Maze Therapeutics
MAZE
31.37
-1.06
-3.27%
Maze Therapeutics
US · MAZE
#2998 by market cap
Listed 2025
31.37
-1.06
-3.27%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Company notice
Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sohn Catherine A.SEC · 2025/9/25
-
Rating change
Wedbush Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/9/23
-
Company notice
Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sohn Catherine A.SEC · 2026/1/9
-
H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/11/11
-
Rating change
J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy RatingMarket Newswire · 2026/10/27
-
J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $51Market Newswire · 2026/11/11
-
Rating change
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX) and Aytu BioScience (AYTU)TipRanks · 2026/9/23
-
Company notice
Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Third Rock Ventures IV, L.P.SEC · 2025/11/6
-
Company notice
Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Third Rock Ventures IV, L.P.SEC · 2025/2/4
-
Rating change
CCORF Initiates Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $75Market Newswire · 2026/10/19
-
Rating change
Citi Initiates Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $50Market Newswire · 2026/9/24
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX)TipRanks · 2026/9/23
-
Rating change
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Maze Therapeutics, Inc. (MAZE) and Abbott Laboratories (ABT)TipRanks · 2026/10/21
-
Rating change
A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $46 to $110Market Newswire · 2026/9/23
-
Rating change
Maze Therapeutics, Inc. (MAZE) Gets a Buy From Wells FargoTipRanks · 2026/10/15
-
Wells Fargo Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/11/11
-
Company notice
GiXo: Gix Makes Maze Co., Ltd. a Subsidiary - Strengthening the System to Promote the Data Infrastructure Utilization Service “CU/ADS (Quads)”JPX · 2025/10/2
-
Rating change
HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price TargetBenzinga · 2026/9/24
-
Citi Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/11/10
-
BTIG Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $46Market Newswire · 2026/11/10
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Mirum Pharmaceuticals (MIRM)TipRanks · 2026/9/10
-
Wells Fargo Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/10/15
-
H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/10/26
-
Rating change
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Ionis Pharmaceuticals (IONS)TipRanks · 2026/9/23
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE)TipRanks · 2026/9/22
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Maze Therapeutics discussion 0 comments